New drug application submitted for Journey Medical’s rosacea candidate

A new drug application has been submitted to the FDA for oral DFD-29 for the treatment of rosacea, Journey Medical announced in a press release.
In two phase 3 clinical trials, patients treated with DFD-29 (minocycline hydrochloride modified release capsules 40 mg) showed superior efficacy to those treated with both placebo and doxycycline 40 mg (Oracea, Galderma).
Journey used data from these studies to support the NDA.
“This NDA submission is a significant milestone for Journey Medical and we look forward to collaborating with the FDA during its review to bring DFD-29, a potentially

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.